UK markets closed
  • NIKKEI 225

    28,523.26
    -110.20 (-0.38%)
     
  • HANG SENG

    29,962.47
    +320.19 (+1.08%)
     
  • CRUDE OIL

    53.28
    +0.30 (+0.57%)
     
  • GOLD FUTURES

    1,868.00
    +27.80 (+1.51%)
     
  • DOW

    31,172.98
    +242.46 (+0.78%)
     
  • BTC-GBP

    25,793.47
    +581.42 (+2.31%)
     
  • CMC Crypto 200

    697.06
    -3.56 (-0.51%)
     
  • ^IXIC

    13,475.96
    +278.78 (+2.11%)
     
  • ^FTAS

    3,816.31
    +22.40 (+0.59%)
     

Global $100+ Billion Autoinjectors (Disposable, Reusable) Markets to 2025

Research and Markets
·3-min read

Dublin, Dec. 16, 2020 (GLOBE NEWSWIRE) -- The "Global Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular Diseases, Diabetes), Type (Disposable, Reusable), Route of Administration (Subcutaneous, Intramuscular), End-user (Hospital) and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.

Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices.

The rheumatoid arthritis segment accounted for the largest share of the autoinjectors market in 2020

Based on therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapies (cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest market share of autoinjectors market. The large share of this segment is mainly due to the high prevalence of rheumatoid arthritis.

The subcutaneous segment is projected to grow at the highest CAGR during the forecast period

Based on route of administration, the autoinjectors market is segmented into intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anemia, and cancer. The subcutaneous segment is projected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.

North America accounted for the largest share of the autoinjectors market in 2020

The autoinjectors market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Latin America, and the Middle East & Africa. North America was the largest regional market for autoinjectors. Growth in the North American market is majorly driven by factors such as the rising incidence of anaphylaxis and the presence of favorable reimbursements. Moreover, the US and Canada are developed economies with high awareness and adoption rates for advanced devices such as autoinjectors, which is beneficial for market growth. Furthermore, other micro-economic indicators such as rising healthcare expenditures, high affordability rate, and the improving regulatory scenario are also major factors contributing to market growth.

Market Dynamics

Drivers

  • Growing Prevalence of Targeted Therapies

  • Rising Incidence of Anaphylaxis

  • Increasing Number of Regulatory Approvals

  • Availability of Generic Versions of Autoinjectors

  • Favorable Reimbursements and Government Support

  • Ease of Use Increasing the Preference for Self-Administration

Restraints

  • Alternative Drug Delivery Modes

  • Research, Development, and Launch of Oral Diabetic Agents and Oral Insulin

  • Development of Nasal Epinephrine Sprays

Opportunities

  • Patent Expiry of Biologics to Drive the Demand for Biosimilars

  • Need to Limit Patient Visits and Physical Contact

Challenges

  • Development of Autoinjectors for Multiple Drug Viscosities

  • Lack of Proper Training for Using Autoinjectors

COVID-19 Impact on the Autoinjectors Market

Average Selling Price Trends

Value Chain Analysis

Ecosystem Analysis

Companies Mentioned

  • Abbvie Inc.

  • Amgen

  • Antares Pharma, Inc.

  • Bayer AG

  • Becton, Dickinson and Company

  • Bespak

  • Bristol-Myers Squibb Company

  • Eli Lilly and Company

  • F. Hoffmann-La Roche

  • GlaxoSmithKline plc

  • Haselmeier

  • Johnson & Johnson (J&J)

  • Medeca Pharma AB

  • Merck KGaA

  • Meridian Medical Technologies, Inc. (A Pfizer Company)

  • Mylan

  • Owen Mumford

  • Ravimed

  • SHL Medical

  • Teva Pharmaceutical Industries

  • Ypsomed

For more information about this report visit https://www.researchandmarkets.com/r/1nppcr

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900